triazoles has been researched along with deferiprone in 132 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 43 (32.58) | 29.6817 |
2010's | 81 (61.36) | 24.3611 |
2020's | 8 (6.06) | 2.80 |
Authors | Studies |
---|---|
Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R | 1 |
Nathan, DG | 1 |
Kontoghiorghes, GJ | 7 |
Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM | 1 |
Porter, JB | 2 |
Hershko, C | 2 |
Cabantchik, ZI; El, RB; Glickstein, H; Shvartsman, M | 1 |
El Beshlawy, A | 1 |
Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 1 |
Kolnagou, A; Kontoghiorghes, GJ | 2 |
Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
Fischer, R; Harmatz, P; Nielsen, P; Piga, A | 1 |
Greenberg, PL | 1 |
Neufeld, EJ | 1 |
Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC | 1 |
Barton, JC | 1 |
Rose, C | 1 |
Maggio, A | 1 |
Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N | 1 |
Bernhardt, PV | 1 |
Hajjizadeh, M; Heli, H; Jabbari, A; Karimian, K; Moosavi-Movahedi, AA; Shafiee, A | 1 |
Goldberg, SL | 1 |
Berdoukas, V; Modell, B | 1 |
Bring, P; Ford, JA; Partovi, N; Yoshida, EM | 1 |
Kwiatkowski, JL | 1 |
Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S | 1 |
Aguilar, M; Moats, R; Nelson, MD; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
Edwards, J; Ibrahim, AS; Spellberg, B | 1 |
Cappellini, MD; Porter, JB; Taher, AT; Vichinsky, EP | 1 |
Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T | 1 |
Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A | 1 |
Kim, DM; Neupane, GP | 1 |
Cappellini, MD; Pattoneri, P | 1 |
Ahmad, F; Amani, M; Babaahmadi, A; Divsalar, A; Farzami, B; Hakimelahi, GH; Kamarie, M; Karimian, K; Moosavi-Movahedi, AA; Mousavy, SJ; Poursasan, N; Riazi, GH; Saboury, AA; Shafiee, A; Tsai, FY | 1 |
Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH | 1 |
Chan, GC; Chan, S; Ha, SY; Ho, PL | 1 |
Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y | 1 |
Fibach, E; Prus, E | 1 |
Brissot, P; Cannie, I; Gaboriau, F; Gouffier, L; Leray, AM; Lescoat, G; Loréal, O; Ropert, M; Troadec, MB | 1 |
Telfer, P | 1 |
Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V | 1 |
Fausel, CA | 1 |
Balocco, M; Carrara, P; Forni, GL; Pinto, V | 1 |
Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A | 1 |
Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K | 1 |
Inati, A; Khoriaty, E; Musallam, KM; Taher, AT | 1 |
Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G | 1 |
Porter, JB; Shah, FT | 1 |
Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS | 1 |
Crichton, RR; Della Corte, L; Dexter, DT; Freinbichler, W; Statton, SA; Tipton, KF; Ward, RJ; Weinberger, P; Whitmore, C | 1 |
Balooch, FD; Golbafan, MR; Iranmanesh, M; Jamilaldin Fatemi, S; Saljooghi, AS | 1 |
Mullié, C; Sonnet, P | 1 |
Berdoukas, V; Coates, T; Farmaki, K; Wood, JC | 1 |
Chao, NJ; Kanda, J; Kawabata, H | 1 |
Christoulas, D; Terpos, E; Voskaridou, E | 1 |
Chaiyakunapruk, N; Luangasanatip, N; Upakdee, N; Wong, P | 1 |
Aloj, G; Bonifazi, F; Cappellini, MD; Cassarà, F; Ceci, A; Cianciulli, P; Filosa, A; Fucharoen, S; Gluud, C; Grady, RW; Harmatz, P; Iacono, A; Kattamis, A; Maggio, A; Porter, JB; Prossomariti, L; Vitrano, A; Wood, J | 1 |
Musallam, KM; Taher, AT | 1 |
El-Beshlawy, A; Evangeli, M; Porter, JB | 1 |
Saljooghi, AS | 1 |
Kohli, S; Saxena, R; Verma, IC | 1 |
Pankaew, T; Torcharus, K | 1 |
Fernandes, JL | 1 |
Karakukcu, C; Karakukcu, M; Ozdemir, MA; Patiroglu, T; Tang, PH; Torun, YA; Unal, E | 1 |
Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ | 1 |
Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L | 1 |
Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S | 1 |
Cappellini, MD; Hoffbrand, AV; Taher, A | 1 |
Agapidou, A; Economou, M; Efthimia, V; Neokleous, N; Perifanis, V; Teli, A; Vetsiou, E | 1 |
Aylak, F; Canatan, D; Erdoğan, E; Ormeci, AR; Vural, H | 1 |
Ruivard, M | 1 |
Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A | 1 |
Kurtoglu, E; Uygun, V | 1 |
Al Rawas, A; Bashir, W; Pathare, A; Tony, S; Wali, Y; Zachariah, M | 1 |
Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G | 1 |
Dahooee Balooch, F; Ebrahimpour, R; Fatemi, SJ; Iranmanesh, M | 1 |
Brittenham, GM; Olivieri, NF | 1 |
Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C | 1 |
Balooch, FD; Fatemi, SJ; Golbafan, MR; Iranmanesh, M | 1 |
Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J | 1 |
Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ | 1 |
Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R | 1 |
de Witte, T | 1 |
Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS | 1 |
Balooch, FD; Fatemi, SJ; Iranmanesh, M | 1 |
Huang, L; Jiang, H; Xia, S; Zhang, W | 1 |
Economou, M; Garypidou, V; Gombakis, N; Kargioti, A; Neokleous, N; Papachristou, F; Teli, A; Theodoridou, S; Vakalopoulou, S; Vlachaki, E; Vyzantiadis, TA | 1 |
Merkel, DG; Nagler, A | 1 |
Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY | 1 |
Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V | 1 |
Aaseth, J; Andersen, O; Cao, Y; Skaug, MA | 1 |
Genc, GE; Gumuslu, S; Kupesiz, A; Kurtoglu, E; Ozturk, Z | 1 |
Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y | 1 |
Attri, SV; Bansal, D; Bhatia, P; Marwaha, RK; Totadri, S; Trehan, A | 1 |
Garbowski, M; Porter, J; Vlachodimitropoulou Koumoutsea, E | 1 |
Genc, GE; Gumuslu, S; Kupesiz, A; Ozturk, Z | 1 |
Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA | 1 |
Chen, V; Clemons, KV; Cohen, K; Ferreira, JA; Haagensen, JA; Hsu, JL; Martinez, M; Nazik, H; Penner, JC; Spormann, AM; Stevens, DA | 1 |
El Rassi, F; Saliba, AN; Taher, AT | 1 |
Aygener, N; Eyigor, H; Kurtoglu, E; Osma, U; Yilmaz, MD | 1 |
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E | 1 |
Kontoghiorghe, CN; Kontoghiorghes, GJ | 1 |
Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
Gomber, S; Jain, P; Narang, M; Sharma, S | 1 |
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F | 1 |
Bentley, A; Caruso, V; Cuccia, L; D'Ascola, DG; Filosa, A; Frizziero, L; Hanif, A; Meloni, A; Pepe, A; Putti, MC; Rossi, G; Spasiano, A | 1 |
Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S | 1 |
Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
Leitch, HA; Wong, SA | 1 |
Aydogdu, S; Bayramoglu, Z; Dursun, M; Karagenc, AO; Karakas, Z; Karaman, S; Tugcu, D; Yilmaz, Y | 1 |
Sivaramakrishnan, G; Sridharan, K | 1 |
Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M | 1 |
Sari, TT; Wahidiyat, PA; Yosia, M | 1 |
Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ | 1 |
Bintoro, SUY; Qatrunnada, H; Wahyuni, S | 1 |
Borella, E; Della Pasqua, O; Magni, P; Oosterholt, S | 1 |
Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E | 1 |
Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ | 1 |
Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E | 1 |
Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y | 1 |
Aydinok, Y | 1 |
47 review(s) available for triazoles and deferiprone
Article | Year |
---|---|
Clinical research: a tale of two studies.
Topics: Benzoates; Biomedical Research; Cooperative Behavior; Deferasirox; Deferiprone; Drug Design; Drug Industry; Humans; Iron Chelating Agents; Pyridones; Thalassemia; Triazoles | 2003 |
Monitoring and treatment of iron overload: state of the art and new approaches.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Magnetics; Pyridones; Triazoles | 2005 |
Treating iron overload: the state of the art.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Survival Analysis; Triazoles | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles | 2005 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2006 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles | 2007 |
Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Triazoles | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles | 2007 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2008 |
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Mutation; Phlebotomy; Pyridones; Triazoles | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Overload; Pyridones; Siderophores; Triazoles | 2008 |
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbial Viability; Mucorales; Mucormycosis; Pyridones; Triazoles | 2008 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2009 |
Update on survival in thalassemia major.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Pyridones; Survival Rate; Treatment Outcome; Triazoles | 2009 |
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Triazoles | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2010 |
Iron overload and allogeneic hematopoietic stem-cell transplantation.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Transplantation, Homologous; Triazoles | 2011 |
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; MEDLINE; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Treatment Outcome; Triazoles; Ventricular Function | 2011 |
Iron chelation therapy for transfusional iron overload: a swift evolution.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles | 2011 |
Past, present & future scenario of thalassaemic care & control in India.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Female; Genetic Carrier Screening; Humans; India; Male; Preimplantation Diagnosis; Prenatal Diagnosis; Pyridones; Thalassemia; Triazoles | 2011 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles | 2013 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles | 2013 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
Chelation in metal intoxication--Principles and paradigms.
Topics: Administration, Oral; Antidotes; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Heavy Metal Poisoning; Humans; Penicillamine; Poisoning; Pyridones; Succimer; Triazoles; Trientine; Unithiol | 2015 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles | 2016 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles | 2016 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2017 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles | 2018 |
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles | 2022 |
Iron chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Combination chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Quality of Life; Triazoles | 2023 |
4 trial(s) available for triazoles and deferiprone
Article | Year |
---|---|
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult | 2009 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Iron Chelating Agents; Male; Myocardium; Patient Compliance; Prospective Studies; Pyridones; Stroke Volume; Triazoles; Young Adult | 2012 |
The effects of chelators on zinc levels in patients with thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; Humans; Iron Chelating Agents; Male; Pyridones; Triazoles; Young Adult; Zinc | 2013 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles | 2015 |
81 other study(ies) available for triazoles and deferiprone
Article | Year |
---|---|
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles | 2001 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2003 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles | 2005 |
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
Topics: Animals; Benzoates; Catalysis; Cell Line; Cell Survival; Cells; Cytosol; Deferasirox; Deferiprone; Deferoxamine; Endosomes; Humans; Iron; Iron Chelating Agents; Mice; Microscopy, Fluorescence; Mitochondria; Pyridones; Time Factors; Triazoles | 2005 |
The Egyptian experience with oral iron chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Egypt; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles | 2005 |
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Liver; Organ Size; Pyridones; Triazoles | 2006 |
[Post transfusionnal iron overload].
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Pyridones; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles | 2007 |
Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode.
Topics: Benzoates; Deferasirox; Deferiprone; Electrochemistry; Ion-Selective Electrodes; Iron Chelating Agents; Microscopy, Electron, Scanning; Nickel; Oxidation-Reduction; Pyridones; Triazoles | 2008 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles | 2008 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles | 2008 |
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Gerbillinae; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Siderophores; Tissue Distribution; Triazoles | 2008 |
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Iron Chelating Agents; Pyridones; Risk Assessment; Siderophores; Triazoles | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure | 2008 |
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; Triazoles; Vibrio Infections; Vibrio vulnificus | 2009 |
The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
Topics: Benzoates; beta-Thalassemia; Circular Dichroism; Deferasirox; Deferiprone; Hemoglobins; Humans; Iron Chelating Agents; Pyridones; Spectrometry, Fluorescence; Structure-Activity Relationship; Triazoles | 2009 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles | 2010 |
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferasirox; Deferiprone; Dose-Response Relationship, Drug; Female; Ferritins; Hepatocytes; Humans; Iron; Iron Chelating Agents; Liver Neoplasms; Molecular Structure; Pyridones; Receptors, Transferrin; Triazoles | 2010 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2010 |
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult | 2011 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Electrocardiography; Female; Ferritins; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Sex Factors; Siderophores; Siderosis; Triazoles | 2010 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemistry; Injections, Intraventricular; Iron Chelating Agents; Male; Microdialysis; Neuroprotective Agents; Parkinsonian Disorders; Pyridones; Rats; Rats, Sprague-Dawley; Sorbic Acid; Triazoles | 2011 |
Chelation of cadmium by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Cadmium Compounds; Cadmium Poisoning; Chelation Therapy; Deferasirox; Deferiprone; Drug Combinations; Iron Chelating Agents; Iron Compounds; Male; Pyridones; Rats; Rats, Wistar; Spectrophotometry, Atomic; Triazoles | 2011 |
In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.
Topics: Antimalarials; Benzoates; Chloroquine; Deferasirox; Deferiprone; Deferoxamine; Glutathione; Hemeproteins; Hemin; Hydrogen Peroxide; Inhibitory Concentration 50; Iron Chelating Agents; Plasmodium falciparum; Pyridones; Structure-Activity Relationship; Triazoles; Triterpenes; Ursolic Acid | 2011 |
Iron chelation in thalassemia: time to reconsider our comfort zones.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles | 2011 |
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles | 2011 |
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Markov Chains; Models, Economic; Pyridones; Quality-Adjusted Life Years; Thailand; Triazoles | 2011 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles | 2011 |
Chelation of aluminum by combining deferasirox and deferiprone in rats.
Topics: Aluminum; Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Iron; Male; Pyridones; Rats; Rats, Wistar; Triazoles | 2012 |
Health-related quality of life in Thai thalassemic children treated with iron chelation.
Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles | 2011 |
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Triazoles; Ubiquinone; Young Adult | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2012 |
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Female; Greece; Humans; Hypercalciuria; Hyperuricemia; Iron Chelating Agents; Iron Overload; Male; Nephrolithiasis; Postoperative Complications; Pyridones; Splenectomy; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Erythroid Precursor Cells; Female; Ferritins; Flow Cytometry; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Linear Models; Male; Multivariate Analysis; Myeloid Progenitor Cells; Pyridones; Splenectomy; Triazoles; Young Adult | 2013 |
Iron-chelation therapy with oral chelators in patients with thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Middle Aged; Pyridones; Retrospective Studies; Splenectomy; Triazoles; Young Adult | 2013 |
Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Female; Ferritins; Humans; Infant; Iron Chelating Agents; Male; Pyridones; Retrospective Studies; Triazoles; Vitamin D Deficiency | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult | 2013 |
Chelation of chromium(VI) by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Body Weight; Chelating Agents; Chelation Therapy; Chromium; Deferasirox; Deferiprone; Male; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles | 2013 |
Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Disease Models, Animal; Drug Therapy, Combination; Male; Mercury; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles; Volatilization | 2013 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles | 2013 |
Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Lead; Male; Models, Biological; Molecular Structure; Pyridones; Rats; Rats, Wistar; Triazoles | 2014 |
Laboratory investigation of platelet function in patients with thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyridones; Triazoles; Young Adult | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress.
Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Glutathione Transferase; Humans; Iron Chelating Agents; Male; Oxidative Stress; Oxidoreductases; Peroxiredoxins; Pyridones; Thioredoxin Reductase 1; Thioredoxins; Triazoles; Young Adult | 2015 |
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Eruptions; Drug Therapy, Combination; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Prospective Studies; Proteinuria; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2015 |
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Topics: Benzoates; Cell Line; Deferasirox; Deferiprone; Deferoxamine; Drug Synergism; Humans; Intracellular Space; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2015 |
Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Male; Minerals; Pyridones; Triazoles; Young Adult | 2016 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles | 2015 |
Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm.
Topics: Antifungal Agents; Aspergillus fumigatus; Benzoates; Biofilms; Chlorides; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Plankton; Pyridones; Spores, Fungal; Tetrazolium Salts; Triazoles | 2015 |
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Hearing Loss, Sensorineural; Humans; Iron Chelating Agents; Male; Middle Aged; Pyridones; Triazoles; Young Adult | 2015 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Female; Fetus; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyridones; Triazoles | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2017 |
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Health Care Costs; Humans; Iron Chelating Agents; Italy; Pyridones; Treatment Outcome; Triazoles | 2017 |
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; India; Iron Chelating Agents; Kidney Function Tests; Liver Function Tests; Male; Prospective Studies; Pyridones; Tertiary Care Centers; Triazoles | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2018 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles | 2018 |
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Thalassemia; Treatment Outcome; Triazoles; Turkey | 2018 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc | 2021 |
Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya.
Topics: Adult; Benzoates; beta-Thalassemia; Costs and Cost Analysis; Deferasirox; Deferiprone; Drug Utilization; Ferritins; Hospitals, General; Humans; Iron Chelating Agents; Pharmaceutical Preparations; Retrospective Studies; Triazoles | 2021 |
Characterisation of individual ferritin response in patients receiving chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2022 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles | 2023 |